Intelligence · Clinical pipeline
Oncology R&D Pipeline
Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Quick answer
Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Top sponsors
- First People's Hospital 474 programs
- Chinese Academy of 400 programs
- United Therapeutics Europe 219 programs
- George Institute for 172 programs
- Takeda 163 programs
- HOFFMANN-LA ROCHE 144 programs
- AstraZeneca 143 programs
- MSD Merck Sharp 131 programs
- Regeneron UK 128 programs
- Anaxis Pharma 125 programs
- Telethon Foundation 113 programs
- Novartis India 110 programs
Pipeline programs
-
DESTINYEndometrial01
AstraZeneca AB
HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer
1 trial -
DICES
COLLEGIUM PHARMACEUTICAL, INC
Breast cancer
1 trial -
DLY201619
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-small Cell Lung Cancer Stage IIIA
1 trial -
DOCETAXEL
Pfizer Australia Pty Ltd
Non-Small Cell Lung Cancer (NSCLC)
1 trial -
DS-8201a
Daiichi Sankyo
Advanced (unresectable or metastatic) human epidermal growth receptor 2 (HER2)-expressing/HER2-mutated solid tumors
1 trial -
DS1062-328
Daiichi Sankyo
Locally Advanced or Metastatic Urothelial Carcinoma
1 trial -
DS1062-A-U304
Daiichi Sankyo
Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
1 trial -
DS6000-109
Daiichi Sankyo
Platinum-resistant, high-grade serous ovarian cancer (OVC),high-grade endometrioid OVC, primary peritoneal cancer, or fallopian tube cancer
1 trial -
DS7300-188
Daiichi Sankyo
Small Cell Lung Cancer (SCLC)
1 trial -
DS7300-202
Daiichi Sankyo
Esophageal Squamous Cell Carcinoma (ESCC)
1 trial -
DS8201-724
Daiichi Sankyo
Unresectable, Locally Advanced or Metastatic HER2 positive Gastric or Gastroesophageal Junction Cancer
1 trial -
DS8201-772
Daiichi Sankyo
Ovarian Cancer
1 trial -
DS8201-793
Daiichi Sankyo
Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer
1 trial -
DS8201-854
Daiichi Sankyo
HER2-expressing endometrial cancer (IHC 3+/2+)
1 trial -
DS8201-A-U302
Daiichi Sankyo
Metastatic breast cancer
1 trial -
DS8201-A-U305
Daiichi Sankyo
High-Risk HER2-Positive Breast Cancer
1 trial -
DS8201-A-U306
Daiichi Sankyo
Metastatic Gastric Adenocarcinoma
1 trial -
DUO-O/D081RC00001
AstraZeneca AB
Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian or primary peritoneal cancer
1 trial -
DZ2024B0002
Lacuna Pharma Pty Ltd
Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
1 trial -
Dabrafenib
Novartis Pharmaceuticals
Malignant Melanoma
1 trial -
Dactinomycin
Children's Hospital of Fudan University
Adult Kidney Wilms Tumor
1 trial -
Darbepoetin alfa
Amgen
Non-Small Cell Lung Cancer
1 trial -
Darleukin, Fibromun
Philogen S.p.A.
Malignant melanoma of the skin in patients with locally advanced and fully resectable melanoma with/without prior therapy and presence of injectable cutaneous and/or subcutaneous or nodal lesions
1 trial -
Darovasertib
IDEAYA Biosciences
Uveal Melanoma
2 trials -
Dato-DXd
AstraZeneca
Breast Cancer
2 trials -
Datopotamab deruxtecan for Stage I-III Triple-negative Bre…
AstraZeneca AB
Stage I-III Triple-negative Breast Cancer with residual invasive disease after neoadjuvant systemic therapy.
1 trial -
Datopotamab deruxtecan, DOCETAXEL
Daiichi Sankyo
Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
1 trial -
Datopotamab deruxtecan, DOCETAXEL
AstraZeneca AB
TROP2 NMR-positive advanced or metastatic non-squamous non-small cell lung cancer without actionable genomic alterations.
1 trial -
Decitabine
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial -
Decitabine
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia, Adult
1 trial -
Decitabine plus HAAG regimen
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial -
Dendritic cell immunotherapy
NORTHWEST BIOTHERAPEUTICS INC
Prostate Cancer
1 trial -
Denosumab
Amgen
Cancer
1 trial -
Dinutuximab
United Therapeutics Europe Ltd
Small Cell Lung Cancer
1 trial -
Distress Thermometer and Problems List
United Therapeutics Europe Ltd
Cancer
1 trial -
Docetaxel
Sanofi Pasteur
Non-small Cell Lung Cancer
1 trial -
Docetaxel
AstraZeneca
Prostate Cancer
1 trial -
Docetaxel+lobaplatin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lobaplatin and Gemcitabine in Combination, Second-line Treatments on Advanced Osteosarcoma
1 trial -
Docetaxel, cisplatin and fluorouracil
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
Dociparstat
Jazz Pharmaceuticals Ireland Limited
Acute Myeloid Leukemia
1 trial -
Domvanalimab
Arcus Biosciences
Advanced Upper Gastrointestinal Tract Adenocarcinoma
1 trial -
Dostarlimab
GlaxoSmithKline
Neoplasms, Head and Neck
1 trial -
Doxorubicin
Takeda
Hodgkin Lymphoma
1 trial -
Doxorubicine + docetaxel sequential
Sanofi Pasteur
Breast Neoplasms
1 trial -
Drug: Ivonescimab Injection
Summit Therapeutics
Metastatic Colorectal Cancer (CRC)
1 trial -
Durvalumab
AstraZeneca
Non-Small Cell Lung Cancer
2 trials -
Durvalumab
Arcus Biosciences
Non-Small Cell Lung Cancer
1 trial -
Durvalumab
AstraZeneca
Hepatocellular Carcinoma
2 trials
Frequently asked questions
How many oncology pipeline programs are tracked?
5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.
Where does pipeline data come from?
ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.